ARMP Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of --. Armata Pharmaceuticals's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 241.46%. On the other hand Perspective Therapeutics has an analysts' consensus of $15.58 which suggests that it could grow by 568.37%. Given that Perspective Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Perspective Therapeutics is more attractive than Armata Pharmaceuticals.

Armata Pharmaceuticals has a beta of 0.887, which suggesting that the stock is 11.295% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.251, suggesting its more volatile than the S&P 500 by 25.149%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Armata Pharmaceuticals's net income of -$5.5M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 742.69x versus 13.23x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Armata Pharmaceuticals's net margin of 12.11%. Armata Pharmaceuticals's return on equity of -- beat Electromed's return on equity of 15.91%.

Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 241.46%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.1%. Given that Armata Pharmaceuticals has higher upside potential than Electromed, analysts believe Armata Pharmaceuticals is more attractive than Electromed.

Armata Pharmaceuticals has a beta of 0.887, which suggesting that the stock is 11.295% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Armata Pharmaceuticals's net income of -$5.5M is lower than Electromed's net income of $2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Electromed's PE ratio is 32.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 742.69x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Innoviva has a net margin of -- compared to Armata Pharmaceuticals's net margin of 22.15%. Armata Pharmaceuticals's return on equity of -- beat Innoviva's return on equity of 3.44%.

Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 241.46%. On the other hand Innoviva has an analysts' consensus of $19.00 which suggests that it could grow by 9.95%. Given that Armata Pharmaceuticals has higher upside potential than Innoviva, analysts believe Armata Pharmaceuticals is more attractive than Innoviva.

Armata Pharmaceuticals has a beta of 0.887, which suggesting that the stock is 11.295% less volatile than S&P 500. In comparison Innoviva has a beta of 0.564, suggesting its less volatile than the S&P 500 by 43.648%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Innoviva quarterly revenues of $91.8M. Armata Pharmaceuticals's net income of -$5.5M is lower than Innoviva's net income of $20.3M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Innoviva's PE ratio is 90.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 742.69x versus 3.83x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of 35.65%. Armata Pharmaceuticals's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

Armata Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 241.46%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 517.02%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

Armata Pharmaceuticals has a beta of 0.887, which suggesting that the stock is 11.295% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Armata Pharmaceuticals's net income of -$5.5M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 78.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 742.69x versus 3.65x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.